Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Nizzardo, M ^a   Simone, C ^a   Rizzo, F ^a   Ulzi, G ^a   Ramirez, A ^a   Rizzuti, M ^a   Bordoni, A ^a   Bucchia, M ^a   Gatti, S ^a   Bresolin, N ^a   Comi, G P ^a   Corti, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; OLIGONUCLEOTIDE; SOD1 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; APOPTOSIS; AXON; C57BL MOUSE; CELL DEATH; CYTOLOGY; DISEASE COURSE; DISEASE MODEL; GENE SILENCING; GENETICS; HELA CELL LINE; HUMAN; INDUCED PLURIPOTENT STEM CELL; INFLAMMATION; METABOLISM; MOTONEURON; MOUSE; PATHOPHYSIOLOGY; PROTEIN FOLDING; SPINAL CORD; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; AXONS; CELL DEATH; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE SILENCING; HELA CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR NEURONS; OLIGONUCLEOTIDES; PROTEIN FOLDING; SPINAL CORD; SUPEROXIDE DISMUTASE-1;

EID: 84958581191     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21301     Document Type: Article

References (48)

1. Ludolph, A. C., Brettschneider, J., Weishaupt, J. H. Amyotrophic lateral sclerosis. Curr Opin Neurol. 25, 530-535 (2012).
2. Bucchia, M. et al. Therapeutic development in amyotrophic lateral sclerosis. Clin Ther 37, 668-680 (2015).
3. Renton, A. E., Chio, A., Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17 (2014).
4. Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993).
5. Bruijn, L. I. et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327-338 (1997).
6. Bruijn, L. I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854 (1998).
7. Reaume, A. G. et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 13, 43-47 (1996).
8. Pasinelli, P., Brown, R. H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 7, 710-723 (2006).
9. Rotunno, M. S., Bosco, D. A. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Front Cell Neurosci. 7, 253 (2013).
10. Bosco, D. A. et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 13, 1396-1403 (2010).
11. Ezzi, S. A., Urushitani, M., Julien, J. P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 102, 170-178 (2007).
12. Guareschi, S. et al. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci USA 109, 5074-5079 (2012).
13. Forsberg, K. et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PloS One 5 (2010).
14. Gros-Louis, F., Soucy, G., Lariviere, R., Julien, J. P. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 113, 1188-1199 (2010).
15. Haidet-Phillips, A. M. et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 29, 824-828 (2011).
16. Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392 (2006).
17. Yamanaka, K. et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 11, 251-253 (2008).
18. Kang, S. H. et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 16, 571-579 (2013).
19. Muntoni, F., Wood, M. J. Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov. 10, 621-637 (2011).
20. Summerton, J., Weller, D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195 (1997).
21. Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435-442 (2013).
22. Mitrpant, C. et al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PloS One 8 (2013).
23. Zhou, H. et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther. 24, 331-342 (2013).
24. Porensky, P. N. et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. 21, 1625-1638 (2012).
25. Nizzardo, M. et al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Delta7 mouse model phenotype. Clin Ther. 36, 340-356 e345 (2014).
26. Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 74, 637-647 (2013).
27. Morcos, P. A. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos. Biochem Biophys Res Commun. 358, 521-527 (2007).
28. Corti, S. et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med. 4, 165ra162 (2012).
29. Simone, C. et al. iPSC-Derived neural stem cells act via kinase inhibition to exert neuroprotective effects in spinal muscular atrophy with respiratory distress type 1. Stem cell reports. 3, 297-311 (2014).
30. Ferrera, L. et al. An Italian dominant FALS Leu144Phe SOD1 mutation: genotype-phenotype correlation. Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 4, 167-170 (2003).
31. Kiskinis, E. et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell stem cell 14, 781-795 (2014).
32. Przedborski, S. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. The neurologist 10, 1-7 (2004).
33. Foust, K. D. et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 21, 2148-2159 (2013).
34. Smith, R. A. et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 116, 2290-2296 (2006).
35. Rizzo, F. et al. Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci. 71, 999-1015 (2014).
36. Kerman, A. et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 119, 335-344 (2010).
37. Brotherton, T. E. et al. Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci USA 109, 5505-5510 (2012).
38. Pickles, S. et al. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum Mol Genet. 22, 3947-3959 (2013).
39. Rakhit, R. et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med. 13, 754-759 (2007).
40. Miller, R. G., Mitchell, J. D., Moore, D. H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 3, CD001447 (2012).
41. Dirren, E. et al. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol. 2, 167-184 (2015).
42. Miller, T. M. et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol. 57, 773-776 (2005).
43. Ralph, G. S. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 11, 429-433 (2005).
44. Raoul, C. et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 11, 423-428 (2005).
45. Corti, S. et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain. 133, 465-481 (2010).
46. Teng, Y. D. et al. Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med. 4, 165ra164 (2012).
47. Grondard, C. et al. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci. 25, 7615-7622 (2005).
48. Corti, S. et al. Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1. Hum Mol Genet. 15, 167-187 (2006).